Vamil Divan
Stock Analyst at Guggenheim
(4.76)
# 102
Out of 4,479 analysts
150
Total ratings
65.62%
Success rate
19.04%
Average return
Main Sectors:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTE Aerovate Therapeutics | Downgrades: Neutral | n/a | $1.62 | - | 2 | Jun 18, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $9 → $8 | $2.42 | +230.58% | 5 | May 10, 2024 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $77 | $62.64 | +22.92% | 8 | Apr 23, 2024 | |
| VERA Vera Therapeutics | Reiterates: Buy | $56 | $34.93 | +60.32% | 3 | Apr 5, 2024 | |
| TVTX Travere Therapeutics | Downgrades: Neutral | n/a | $8.09 | - | 4 | Mar 27, 2024 | |
| ABBV AbbVie | Maintains: Buy | $188 → $190 | $165.96 | +14.49% | 16 | Mar 22, 2024 | |
| INSM Insmed | Maintains: Buy | $52 → $54 | $64.50 | -16.28% | 3 | Feb 27, 2024 | |
| PFE Pfizer | Initiates: Buy | $36 | $27.83 | +29.36% | 12 | Feb 23, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $19 → $20 | $10.82 | +84.84% | 7 | Sep 7, 2023 | |
| CALT Calliditas Therapeutics AB (publ) | Maintains: Neutral | $21 → $18 | $38.75 | -53.55% | 2 | Aug 18, 2023 | |
| RLMD Relmada Therapeutics | Reiterates: Buy | $26 | $2.99 | +769.57% | 2 | Jun 15, 2023 | |
| SCYX SCYNEXIS | Maintains: Buy | $8 → $9 | $1.95 | +361.54% | 2 | Apr 3, 2023 | |
| GOSS Gossamer Bio | Initiates: Neutral | n/a | $0.96 | - | 1 | Mar 1, 2023 | |
| JNJ Johnson & Johnson | Initiates: Neutral | $161 | $146.03 | +10.25% | 6 | Mar 1, 2023 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $27 → $19 | $15.84 | +19.95% | 7 | Aug 10, 2022 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $95 → $98 | $137.49 | -28.72% | 5 | Aug 8, 2022 | |
| ALKS Alkermes | Maintains: Buy | $36 → $34 | $24.19 | +40.55% | 7 | Jul 28, 2022 | |
| CABA Cabaletta Bio | Maintains: Buy | $20 → $10 | $7.39 | +35.32% | 3 | May 25, 2022 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $51 → $49 | $78.93 | -37.92% | 3 | May 3, 2022 | |
| LLY Eli Lilly | Maintains: Buy | $315 → $356 | $906.71 | -60.74% | 12 | May 2, 2022 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $8 → $6 | $2.06 | +191.26% | 1 | Mar 16, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | $144 → $154 | $34.17 | +350.69% | 9 | Mar 3, 2022 | |
| EOLS Evolus | Upgrades: Buy | n/a | $10.66 | - | 4 | May 6, 2021 | |
| TEVA Teva Pharmaceutical | Maintains: Neutral | n/a | $16.55 | - | 10 | Feb 14, 2019 | |
| GLPG Galapagos NV | Upgrades: Outperform | n/a | $25.34 | - | 3 | Dec 13, 2018 | |
| MRK Merck & Co. | Maintains: Outperform | n/a | $127.72 | - | 5 | Oct 11, 2018 | |
| CRVS Corvus Pharmaceuticals | Assumes: Outperform | n/a | $1.78 | - | 3 | Aug 15, 2018 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | n/a | $40.45 | - | 3 | Jul 27, 2018 | |
| ESPR Esperion Therapeutics | Initiates: Outperform | n/a | $2.34 | - | 2 | Jan 17, 2018 |
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.62
Upside: -
Revance Therapeutics
May 10, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $2.42
Upside: +230.58%
ANI Pharmaceuticals
Apr 23, 2024
Reiterates: Buy
Price Target: $77
Current: $62.64
Upside: +22.92%
Vera Therapeutics
Apr 5, 2024
Reiterates: Buy
Price Target: $56
Current: $34.93
Upside: +60.32%
Travere Therapeutics
Mar 27, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.09
Upside: -
AbbVie
Mar 22, 2024
Maintains: Buy
Price Target: $188 → $190
Current: $165.96
Upside: +14.49%
Insmed
Feb 27, 2024
Maintains: Buy
Price Target: $52 → $54
Current: $64.50
Upside: -16.28%
Pfizer
Feb 23, 2024
Initiates: Buy
Price Target: $36
Current: $27.83
Upside: +29.36%
Sage Therapeutics
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $10.82
Upside: +84.84%
Calliditas Therapeutics AB (publ)
Aug 18, 2023
Maintains: Neutral
Price Target: $21 → $18
Current: $38.75
Upside: -53.55%
Relmada Therapeutics
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $2.99
Upside: +769.57%
SCYNEXIS
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $1.95
Upside: +361.54%
Gossamer Bio
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.96
Upside: -
Johnson & Johnson
Mar 1, 2023
Initiates: Neutral
Price Target: $161
Current: $146.03
Upside: +10.25%
ACADIA Pharmaceuticals
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $15.84
Upside: +19.95%
Neurocrine Biosciences
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $137.49
Upside: -28.72%
Alkermes
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $24.19
Upside: +40.55%
Cabaletta Bio
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $7.39
Upside: +35.32%
Axsome Therapeutics
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $78.93
Upside: -37.92%
Eli Lilly
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $906.71
Upside: -60.74%
Xeris Biopharma Holdings
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $2.06
Upside: +191.26%
Biohaven Pharmaceutical Holding Company
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $34.17
Upside: +350.69%
Evolus
May 6, 2021
Upgrades: Buy
Price Target: n/a
Current: $10.66
Upside: -
Teva Pharmaceutical
Feb 14, 2019
Maintains: Neutral
Price Target: n/a
Current: $16.55
Upside: -
Galapagos NV
Dec 13, 2018
Upgrades: Outperform
Price Target: n/a
Current: $25.34
Upside: -
Merck & Co.
Oct 11, 2018
Maintains: Outperform
Price Target: n/a
Current: $127.72
Upside: -
Corvus Pharmaceuticals
Aug 15, 2018
Assumes: Outperform
Price Target: n/a
Current: $1.78
Upside: -
Bristol-Myers Squibb Company
Jul 27, 2018
Maintains: Neutral
Price Target: n/a
Current: $40.45
Upside: -
Esperion Therapeutics
Jan 17, 2018
Initiates: Outperform
Price Target: n/a
Current: $2.34
Upside: -